Drug name - Cibinqo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

CN105008362A PFIZER Pyrrolo [2, 3-D] Pyrimidine Derivative Used As James Related Kinase (As Jak) Inhibitor
Feb, 2034

(11 years from now)

CN105008362B PFIZER As Associated Janus Kinase (Jak) Inhibitor Of Pyrrolo [2 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

CN107089985A PFIZER As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

CN107089985B PFIZER As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

IN201506803P1 PFIZER Pyrrolo [2 3 D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)
Feb, 2034

(11 years from now)

IN329290B PFIZER Pyrrolo [2, 3, D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP3290421A1 PFIZER Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP3290421B1 PFIZER Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP2958921B1 PFIZER Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)
Feb, 2034

(11 years from now)

EP2958921A1 PFIZER Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives Feb, 2034

(11 years from now)

Drugs and Companies using ABROCITINIB ingredient

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.